CN114423437A - 水溶性o-糖基类黄酮组合物及其制备方法 - Google Patents
水溶性o-糖基类黄酮组合物及其制备方法 Download PDFInfo
- Publication number
- CN114423437A CN114423437A CN202080066335.7A CN202080066335A CN114423437A CN 114423437 A CN114423437 A CN 114423437A CN 202080066335 A CN202080066335 A CN 202080066335A CN 114423437 A CN114423437 A CN 114423437A
- Authority
- CN
- China
- Prior art keywords
- water
- composition
- arginine
- soluble composition
- glycosyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 124
- 229930003935 flavonoid Natural products 0.000 title claims abstract description 53
- 235000017173 flavonoids Nutrition 0.000 title claims abstract description 53
- 238000002360 preparation method Methods 0.000 title description 6
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 70
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 claims abstract description 54
- 229930064664 L-arginine Natural products 0.000 claims abstract description 54
- 235000014852 L-arginine Nutrition 0.000 claims abstract description 54
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 claims abstract description 44
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 claims abstract description 44
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 claims abstract description 44
- 235000005493 rutin Nutrition 0.000 claims abstract description 44
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 claims abstract description 44
- 229960004555 rutoside Drugs 0.000 claims abstract description 44
- 235000010323 ascorbic acid Nutrition 0.000 claims abstract description 37
- 239000011668 ascorbic acid Substances 0.000 claims abstract description 37
- OVSQVDMCBVZWGM-IDRAQACASA-N Hirsutrin Natural products O([C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1)C1=C(c2cc(O)c(O)cc2)Oc2c(c(O)cc(O)c2)C1=O OVSQVDMCBVZWGM-IDRAQACASA-N 0.000 claims abstract description 34
- FVQOMEDMFUMIMO-UHFFFAOYSA-N Hyperosid Natural products OC1C(O)C(O)C(CO)OC1OC1C(=O)C2=C(O)C=C(O)C=C2OC1C1=CC=C(O)C(O)=C1 FVQOMEDMFUMIMO-UHFFFAOYSA-N 0.000 claims abstract description 34
- GXMWXESSGGEWEM-UHFFFAOYSA-N isoquercitrin Natural products OCC(O)C1OC(OC2C(Oc3cc(O)cc(O)c3C2=O)c4ccc(O)c(O)c4)C(O)C1O GXMWXESSGGEWEM-UHFFFAOYSA-N 0.000 claims abstract description 34
- OVSQVDMCBVZWGM-QSOFNFLRSA-N quercetin 3-O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C(C=2C=C(O)C(O)=CC=2)OC2=CC(O)=CC(O)=C2C1=O OVSQVDMCBVZWGM-QSOFNFLRSA-N 0.000 claims abstract description 34
- 229960005070 ascorbic acid Drugs 0.000 claims abstract description 33
- 150000005846 sugar alcohols Chemical class 0.000 claims abstract description 29
- 229910052783 alkali metal Inorganic materials 0.000 claims abstract description 24
- -1 alkali metal salt Chemical class 0.000 claims abstract description 24
- 239000001100 (2S)-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)chroman-4-one Substances 0.000 claims abstract description 23
- QUQPHWDTPGMPEX-UHFFFAOYSA-N Hesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(COC4C(C(O)C(O)C(C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-UHFFFAOYSA-N 0.000 claims abstract description 23
- QUQPHWDTPGMPEX-UTWYECKDSA-N aurantiamarin Natural products COc1ccc(cc1O)[C@H]1CC(=O)c2c(O)cc(O[C@@H]3O[C@H](CO[C@@H]4O[C@@H](C)[C@H](O)[C@@H](O)[C@H]4O)[C@@H](O)[C@H](O)[C@H]3O)cc2O1 QUQPHWDTPGMPEX-UTWYECKDSA-N 0.000 claims abstract description 23
- APSNPMVGBGZYAJ-GLOOOPAXSA-N clematine Natural products COc1cc(ccc1O)[C@@H]2CC(=O)c3c(O)cc(O[C@@H]4O[C@H](CO[C@H]5O[C@@H](C)[C@H](O)[C@@H](O)[C@H]5O)[C@@H](O)[C@H](O)[C@H]4O)cc3O2 APSNPMVGBGZYAJ-GLOOOPAXSA-N 0.000 claims abstract description 23
- 229940025878 hesperidin Drugs 0.000 claims abstract description 23
- VUYDGVRIQRPHFX-UHFFFAOYSA-N hesperidin Natural products COc1cc(ccc1O)C2CC(=O)c3c(O)cc(OC4OC(COC5OC(O)C(O)C(O)C5O)C(O)C(O)C4O)cc3O2 VUYDGVRIQRPHFX-UHFFFAOYSA-N 0.000 claims abstract description 23
- QUQPHWDTPGMPEX-QJBIFVCTSA-N hesperidin Chemical compound C1=C(O)C(OC)=CC=C1[C@H]1OC2=CC(O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@@H](CO[C@H]4[C@@H]([C@H](O)[C@@H](O)[C@H](C)O4)O)O3)O)=CC(O)=C2C(=O)C1 QUQPHWDTPGMPEX-QJBIFVCTSA-N 0.000 claims abstract description 23
- ARGKVCXINMKCAZ-UHFFFAOYSA-N neohesperidine Natural products C1=C(O)C(OC)=CC=C1C1OC2=CC(OC3C(C(O)C(O)C(CO)O3)OC3C(C(O)C(O)C(C)O3)O)=CC(O)=C2C(=O)C1 ARGKVCXINMKCAZ-UHFFFAOYSA-N 0.000 claims abstract description 23
- 238000010438 heat treatment Methods 0.000 claims abstract description 15
- 238000000034 method Methods 0.000 claims abstract description 11
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 claims abstract 3
- 239000004386 Erythritol Substances 0.000 claims description 37
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 claims description 37
- 235000019414 erythritol Nutrition 0.000 claims description 37
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 claims description 37
- 229940009714 erythritol Drugs 0.000 claims description 37
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000000845 maltitol Substances 0.000 claims description 11
- 235000010449 maltitol Nutrition 0.000 claims description 11
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 claims description 11
- 229940035436 maltitol Drugs 0.000 claims description 11
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 7
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 7
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 7
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 7
- 239000000600 sorbitol Substances 0.000 claims description 7
- 235000010356 sorbitol Nutrition 0.000 claims description 7
- 229960002920 sorbitol Drugs 0.000 claims description 7
- 239000000811 xylitol Substances 0.000 claims description 7
- 235000010447 xylitol Nutrition 0.000 claims description 7
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 7
- 229960002675 xylitol Drugs 0.000 claims description 7
- 239000002537 cosmetic Substances 0.000 claims description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 claims description 6
- 239000007787 solid Substances 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 239000002775 capsule Substances 0.000 claims description 4
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 claims description 3
- 229930003451 Vitamin B1 Natural products 0.000 claims description 3
- 229930003779 Vitamin B12 Natural products 0.000 claims description 3
- 229930003537 Vitamin B3 Natural products 0.000 claims description 3
- 229930003761 Vitamin B9 Natural products 0.000 claims description 3
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 claims description 3
- 229940079593 drug Drugs 0.000 claims description 3
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 239000000499 gel Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 229960003512 nicotinic acid Drugs 0.000 claims description 3
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinic acid amide Natural products NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 claims description 3
- 239000000047 product Substances 0.000 claims description 3
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 claims description 3
- 229960003495 thiamine Drugs 0.000 claims description 3
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 claims description 3
- 239000012049 topical pharmaceutical composition Substances 0.000 claims description 3
- 235000010374 vitamin B1 Nutrition 0.000 claims description 3
- 239000011691 vitamin B1 Substances 0.000 claims description 3
- 235000019163 vitamin B12 Nutrition 0.000 claims description 3
- 239000011715 vitamin B12 Substances 0.000 claims description 3
- 235000019160 vitamin B3 Nutrition 0.000 claims description 3
- 239000011708 vitamin B3 Substances 0.000 claims description 3
- 235000019158 vitamin B6 Nutrition 0.000 claims description 3
- 239000011726 vitamin B6 Substances 0.000 claims description 3
- 235000019159 vitamin B9 Nutrition 0.000 claims description 3
- 239000011727 vitamin B9 Substances 0.000 claims description 3
- 229940011671 vitamin b6 Drugs 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 235000015872 dietary supplement Nutrition 0.000 claims description 2
- 239000000839 emulsion Substances 0.000 claims description 2
- 239000002702 enteric coating Substances 0.000 claims description 2
- 238000009505 enteric coating Methods 0.000 claims description 2
- 235000013305 food Nutrition 0.000 claims description 2
- 230000036541 health Effects 0.000 claims description 2
- 239000000865 liniment Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 150000002340 glycosyl compounds Chemical class 0.000 claims 1
- 239000006072 paste Substances 0.000 claims 1
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 description 40
- 238000002844 melting Methods 0.000 description 27
- 230000008018 melting Effects 0.000 description 27
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 17
- 229960005055 sodium ascorbate Drugs 0.000 description 17
- 235000010378 sodium ascorbate Nutrition 0.000 description 17
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 17
- 239000004570 mortar (masonry) Substances 0.000 description 12
- 239000000523 sample Substances 0.000 description 11
- 229910052782 aluminium Inorganic materials 0.000 description 7
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 7
- 239000000706 filtrate Substances 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 150000002215 flavonoids Chemical class 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 229940072107 ascorbate Drugs 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 238000002156 mixing Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 description 2
- 239000004475 Arginine Substances 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 2
- 235000009697 arginine Nutrition 0.000 description 2
- 229960003121 arginine Drugs 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000019441 ethanol Nutrition 0.000 description 2
- 239000011874 heated mixture Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- 239000000905 isomalt Substances 0.000 description 2
- 235000010439 isomalt Nutrition 0.000 description 2
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000003260 vortexing Methods 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000000881 depressing effect Effects 0.000 description 1
- 150000004683 dihydrates Chemical group 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 150000004682 monohydrates Chemical group 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 150000003305 rutin Chemical class 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 159000000000 sodium salts Chemical group 0.000 description 1
- 239000008137 solubility enhancer Substances 0.000 description 1
- 150000004684 trihydrates Chemical group 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/52—Adding ingredients
- A23L2/60—Sweeteners
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/175—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/345—Alcohols containing more than one hydroxy group
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/44—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof
- A61K8/442—Aminocarboxylic acids or derivatives thereof, e.g. aminocarboxylic acids containing sulfur; Salts; Esters or N-acylated derivatives thereof substituted by amido group(s)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
- A61K8/676—Ascorbic acid, i.e. vitamin C
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Abstract
水溶性组合物,其包括O‑糖基类黄酮化合物、L‑精氨酸、糖醇以及抗坏血酸或抗坏血酸的碱金属盐。该O‑糖基类黄酮化合物为芸香苷、异槲皮苷或橙皮苷,且该O‑糖基类黄酮化合物与该糖醇之间的摩尔比为1:4.0‑12.0。亦提供制备上文所描述的水溶性组合物的方法,该方法通过合并O‑糖基类黄酮化合物、L‑精氨酸、糖醇以及抗坏血酸或其碱金属盐以形成混合物且在110℃至140℃下将其加热以熔化该混合物来进行。
Description
背景技术
背景
已采用若干方法来改善天然类黄酮(例如,O-糖基类黄酮)的水溶性。一种方法是用碱性氨基酸制备类黄酮的溶液。然而,维持类黄酮的高度水溶性所需的碱性氨基酸的量将溶液的pH提升至类黄酮变得不稳定且随时间推移降解的点。
仍需要研发相较于现有组合物具有类黄酮改良的稳定性、增加的溶解度以及更高的口服吸收率的水溶性O-糖基类黄酮组合物。
发明内容
发明概要
提供水溶性组合物以满足上述需求。组合物包括O-糖基类黄酮化合物、L-精氨酸、糖醇以及抗坏血酸或抗坏血酸的碱金属盐。O-糖基类黄酮化合物为芸香苷、异槲皮苷或橙皮苷,且O-糖基类黄酮化合物与糖醇之间的摩尔比为1:4.0-12.0。
还公开了用于制备上文所描述的水溶性组合物的方法。该方法通过合并O-糖基类黄酮化合物、L-精氨酸、糖醇以及抗坏血酸或其碱金属盐以形成混合物且在110℃至140℃下将混合物加热足以熔化混合物的时间来进行。
本发明的一个或多个实施方案的详情阐述于以下图及描述中。本发明的其他特征、目标及优势将通过描述及权利要求而变得显而易见。本文所引用的所有参考文献均通过引用整体纳入本文中。
实施方案的描述
详细的描述
如上文所概述的,本文公开了水溶性组合物,其含有O-糖基类黄酮(O-glycosylflavonoid)、L-精氨酸、糖醇以及抗坏血酸或抗坏血酸碱金属盐。
O-糖基类黄酮可以是芸香苷(rutin)、橙皮苷(hesperidin)或异槲皮苷(isoquercitrin),且糖醇可以是(但不限于)麦芽糖醇、赤藓糖醇、木糖醇以及山梨糖醇。O-糖基类黄酮与糖醇之间的摩尔比为1:4.0-12.0。在特定组合物中,O-糖基类黄酮与糖醇的摩尔比为1:4.0-8.0。
在水溶性组合物中,O-糖基类黄酮化合物与L-精氨酸之间的摩尔比为1:0.5-2.0。在示例性组合物中,该比率为1:0.7-1.5。
如上文所提及的,水溶性组合物亦包括抗坏血酸或抗坏血酸的碱金属盐。碱金属盐可为钠盐或钾盐。在特定组合物中,碱金属盐为钠盐。O-糖基类黄酮化合物与抗坏血酸或碱金属盐之间的摩尔比为1:0.02-0.5。在组合物中,该比率为1:0.1-0.5。
上文组合物的某些组分(例如,芸香苷、异槲皮苷、橙皮苷以及L-精氨酸)可以无水形式或水合物形式(例如,单水合物形式、二水合物形式或三水合物形式)存在。当组分以水合物形式使用时,呈水合物形式的水包括在其分子量中以用于计算摩尔比。
在上文所描述的水溶性组合物中,O-糖基类黄酮通常以10wt%或更高(例如,20wt%或更高、30wt%或更高以及50wt%或更高)的含量存在。
除O-糖基类黄酮、L-精氨酸、糖醇以及抗坏血酸/抗坏血酸的碱金属盐以外,水溶性组合物亦可包括水溶性维生素,例如维生素B1、维生素B3、维生素B6、维生素B9或维生素B12。组合物中的O-糖基类黄酮与各水溶性维生素的摩尔比可为1:0.01-0.1。
呈固体形式或水性形式的水溶性组合物可呈用于医药、医疗或化妆用途的不同制剂形式。
在一个实施方案中,组合物呈口服制剂形式,例如液体剂、胶囊剂、片剂、丸剂以及凝胶剂。示例性组合物呈胶囊剂或片剂形式,其各自由肠溶包衣形成。组合物可另外含有药物活性剂、药学上可接受的赋形剂或其组合。该实施方案包括作为医药药物、膳食补充品、天然健康产品、化妆品、食品或饮料的组合物。
在另一实施方案中,组合物呈局部制剂形式,例如溶液剂、搽剂、洗剂、乳膏、软膏、糊剂、凝胶剂以及乳胶剂中的一种。局部制剂可进一步含有药物活性剂、局部可接受的赋形剂或其组合。该实施方案包括作为化妆品、皮肤护理品或医药药物的组合物。
由本发明涵盖的示例性组合物包括O-糖基类黄酮、L-精氨酸、糖醇以及抗坏血酸或抗坏血酸碱金属盐作为唯一的活性成分。在另一实例中,组合物包括O-糖基类黄酮、L-精氨酸、糖醇、抗坏血酸或抗坏血酸碱金属盐以及水溶性维生素作为唯一的活性成分。另一种组合物基本上由以下组成或由以下组成:O-糖基类黄酮、L-精氨酸、糖醇以及抗坏血酸或抗坏血酸碱金属盐。另一组合物基本上由以下组成或由以下组成:O-糖基类黄酮、L-精氨酸、糖醇、抗坏血酸或抗坏血酸碱金属盐以及水溶性维生素。本发明的组合物不含溶解性增强剂,例如环糊精。
上文亦概述了用于产生水溶性O-糖基类黄酮组合物的方法。该方法通过合并固体形式的O-糖基类黄酮化合物(例如,芸香苷、异槲皮苷以及橙皮苷)、L-精氨酸、糖醇(例如,麦芽糖醇、赤藓糖醇、木糖醇以及山梨糖醇)以及抗坏血酸或其碱金属盐以形成混合物且在110℃至140℃下将混合物加热足以熔化混合物的时间来进行。加热时间可以是10min至60min(例如,10、15、20、25、30、35、40、45、50、55以及60min)。
在上文方法中,O-糖基类黄酮化合物、L-精氨酸、糖醇及抗坏血酸或其碱金属盐之间的摩尔比为1:0.5-2.0:4.0-12.0:0.02-0.5。在特定方法中,摩尔比为1:0.7-1.5:4.0-8.0:0.1-0.5。
本文公开了某些O-糖基类黄酮的熔点与其溶解度之间的相关性。熔点愈低,溶解度愈高。
在生产方法期间,水溶性O-糖基类黄酮组合物可在生产期间经历褐变过程。不受理论束缚,据信褐变是由糖醇的焦糖化、美拉德反应(Maillard reaction)或其他氧化反应造成的。已出人意料地发现,O-糖基类黄酮组合物在用于熔化O-糖基类黄酮的温度下的褐变可通过添加抗坏血酸或抗坏血酸的碱金属盐来迟延或防止。
由于水溶解度的显著增强,由本发明涵盖的O-糖基类黄酮组合物将具有优良的药代动力学概况,例如口服及皮肤吸收度,进而使得其适用于医药、医疗或化妆用途。
无需进一步详细描述,认为本领域技术人员可基于上文描述最大程度地利用本发明。以下特定实施例仅解释为示例性的,且不以任何方式限制本发明的其余部分。
实施例
实施例1:制备芸香苷/麦芽糖醇/L-精氨酸组合物
制备17ml的L-精氨酸(786mg)及麦芽糖醇(3.0g)的水溶液且将其添加至50ml的含有3g芸香苷的99.5%乙醇中。将混合物搅拌10min、蒸发且在60℃下干燥24h,以得到粉末。将一定量的干粉(226mg,含有100mg芸香苷)添加至10ml的经蒸馏H2O中且通过涡旋混合30s,此时混合物完全溶解。使样品通过0.45μm过滤器且通过HPLC测量滤液中的芸香苷浓度。所测量的芸香苷浓度为9.6mg/ml。
实施例2:制备异槲皮苷/麦芽糖醇/L-精氨酸组合物
制备17ml的L-精氨酸(1.08g)及麦芽糖醇(3.0g)的水溶液且将其添加至50ml的含有3g异槲皮苷的99.5%乙醇中。将混合物搅拌10min、蒸发且在60℃下干燥24h,以得到粉末。将干粉(236mg,含有100mg异槲皮苷)添加至10ml的经蒸馏H2O中且通过涡旋混合30s,直至混合物完全溶解。使样品通过0.45μm过滤器且通过HPLC测量滤液中的异槲皮苷浓度。所测量的异槲皮苷浓度为9.7mg/ml。
实施例3:通过熔化制备芸香苷/赤藓糖醇/抗坏血酸盐/L-精氨酸的组合物
将芸香苷(1.0g)与赤藓糖醇(1.0g)及抗坏血酸钠(60mg)混合且在研钵中研磨。接着添加L-精氨酸(52mg至520mg)且将混合物再次在研钵中研磨。各混合物的摩尔比在下表1中示出。
表1.混合物中的芸香苷/赤藓糖醇/抗坏血酸钠/L-精氨酸的摩尔比
混合物编号 | 芸香苷:赤藓糖醇:抗坏血酸钠:L-精氨酸(mol/mol) |
1-01 | 1:5.4:0.2:0 |
1-02 | 1:5.4:0.2:0.2 |
1-03 | 1:5.4:0.2:0.5 |
1-04 | 1:5.4:0.2:0.7 |
1-05 | 1:5.4:0.2:1.0 |
1-06 | 1:5.4:0.2:1.5 |
1-07 | 1:5.4:0.2:2.0 |
将各混合物在125℃下在铝加热块中加热30min,此时各混合物中的固体完全熔化。
实施例4:通过熔化制备异槲皮苷/赤藓糖醇/抗坏血酸盐/L-精氨酸的组合物
将异槲皮苷(1.0g)与赤藓糖醇(1.5g)及抗坏血酸钠(82mg)混合且在研钵中研磨。接着添加L-精氨酸(72mg至720mg)且将混合物再次在研钵中研磨。各混合物的摩尔比在下表2中示出。
表2.混合物中的异槲皮苷/赤藓糖醇/抗坏血酸钠/L-精氨酸的摩尔比
混合物编号 | 异槲皮苷:赤藓糖醇:抗坏血酸钠:L-精氨酸(mol/mol) |
2-01 | 1:5.9:0.2:0 |
2-02 | 1:5.9:0.2:0.2 |
2-03 | 1:5.9:0.2:0.5 |
2-04 | 1:5.9:0.2:0.7 |
2-05 | 1:5.9:0.2:1.0 |
2-06 | 1:5.9:0.2:1.5 |
2-07 | 1:5.9:0.2:2.0 |
如上文在实施例3中所描述的,将各混合物在125℃下在铝加热块中加热30min,此时各混合物中的固体完全熔化。
实施例5:通过熔化制备橙皮苷/赤藓糖醇/抗坏血酸盐/L-精氨酸的组合物
将橙皮苷(1.0g)与赤藓糖醇(1.0g)及抗坏血酸钠(160mg)混合且在研钵中研磨。接着添加L-精氨酸(55mg至550mg)且将混合物再次在研钵中研磨。各混合物的摩尔比在下表3中示出。
表3.混合物中的橙皮苷/赤藓糖醇/抗坏血酸钠/L-精氨酸的摩尔比
混合物编号 | 橙皮苷:赤藓糖醇:抗坏血酸钠:L-精氨酸(mol:mol) | 加热后的外观 |
3-01 | 1:5.1:0.5:0 | 未熔化 |
3-02 | 1:5.1:0.5:0.2 | 未熔化 |
3-03 | 1:5.1:0.5:0.5 | 部分熔化 |
3-04 | 1:5.1:0.5:0.7 | 部分熔化 |
3-05 | 1:5.1:0.5:1.0 | 完全熔化 |
3-06 | 1:5.1:0.5:1.5 | 完全熔化 |
3-07 | 1:5.1:0.5:2.0 | 完全熔化 |
同样,将各混合物在125℃下在铝加热块中加热30min。如上文表3中所示,当L-精氨酸以至少与橙皮苷等摩尔比存在时,实现了固体的完全熔化。参见混合物3-05、3-06以及3-07。
实施例6:芸香苷组合物的溶解度
将如上文实施例3中所描述的制备的七种芸香苷组合物(41.2mg至51.6mg,各自含有20mg芸香苷)各自添加至2ml经蒸馏H2O的等分试样中,通过涡旋混合器混合30s且在室温下孵育24h。通过将仅20mg芸香苷与2ml经蒸馏H2O混合来制备对照样品(对照1)。通过在2ml经蒸馏H2O中混合芸香苷、赤藓糖醇以及抗坏血酸钠(呈上文表1针对混合物1-01所示的量)来制备第二对照样品。使各样品通过0.45μm过滤器且通过HPLC测量滤液中的芸香苷浓度。结果在下表4中示出。
表4.芸香苷组合物溶解度
出乎意料地,即使当芸香苷与L-精氨酸的摩尔比降低时,赤藓糖醇明显维持高芸香苷溶解度。亦出人意料的,相较于具有相同组成的对照2,混合物1-01显示芸香苷溶解度的4倍增加。混合物1-01通过熔化组分以及加热形成,如上文实施例1中所描述,而对照2的组分在与经蒸馏H2O混合之前不加热。明显地,熔化对于增加混合物中的芸香苷溶解度很重要。
实施例7:异槲皮苷组合物的溶解度
将如实施例4中所描述的制备的七种异槲皮苷组合物(51.6mg至66.0mg,各自含有2mg异槲皮苷)各自添加至2ml经蒸馏H2O的等分试样中,通过涡旋混合器混合30s且在室温下孵育24h。以与上文实施例6中相同的方式来制备对照1及2。使各样品通过0.45μm过滤器且通过HPLC测量滤液中的异槲皮苷浓度。结果在下表5中示出。
表5.异槲皮苷组合物溶解度
出人意料的,即使在异槲皮苷与L-精氨酸的摩尔比降低时,在L-精氨酸的存在下,赤藓糖醇的添加维持增加的异槲皮苷溶解度。
实施例8:橙皮苷组合物的溶解度
将如实施例5中所描述的制备的七种橙皮苷组合物(43.2mg至54.2mg,各自含有2mg橙皮苷)各自添加至2ml经蒸馏H2O的等分试样中,通过涡旋混合器混合30s且在室温下孵育24h。以与上文实施例6及7中相同的方式来制备对照1及2。使各样品通过0.45μm过滤器且通过HPLC测量滤液中的橙皮苷浓度。结果在下表6中示出。
表6.橙皮苷组合物溶解度
出乎意料地,即使在L-精氨酸的量减少时,通过添加赤藓糖醇维持由组合物中的L-精氨酸引起的增加的橙皮苷溶解度。
实施例9:通过赤藓糖醇及L-精氨酸降低O-糖基类黄酮化合物熔点
如下文所描述的制备芸香苷、异槲皮苷以及橙皮苷与赤藓糖醇的样品,以测定在存在或不存在L-精氨酸的情况下的熔化温度。
将两种芸香苷样品(各自1g)与0.7g赤藓糖醇混合且在研钵中研磨。将L-精氨酸(0.26g)添加至两种样品中的一种中。
对于异槲皮苷,将两种1g样品在研钵中与1g赤藓糖醇一起研磨,且将L-精氨酸(0.36g)添加至样品中的一种中。
通过在研钵中将两种1g样品与1g赤藓糖醇一起研磨且将0.52g L-精氨酸添加至一种样品来制备橙皮苷样品。
将所有如上文所制备的样品放置于铝加热块中,将其加热至170℃。记录各样品的熔点。结果在下文呈现于表7中。
表7.赤藓糖醇/L-精氨酸的熔点降低的作用
值得注意的是,赤藓糖醇的添加将所报导的芸香苷熔点(190℃)及异槲皮苷熔点(230℃)明显地降低分别高达50℃及60℃。不能在所使用的实验条件下测量利用赤藓糖醇降低橙皮苷熔点(260℃)。
赤藓糖醇及L-精氨酸两者的添加对于降低熔点甚至更有效。结果显示,在赤藓糖醇及L-精氨酸两者的存在下,芸香苷、异槲皮苷以及橙皮苷的熔点降低了至少70℃。
实施例10:利用糖醇降低芸香苷的熔点
将芸香苷(1.0g)、L-精氨酸(0.39g)以及抗坏血酸钠(60mg)的样品合并且单独地与1.5g赤藓糖醇、木糖醇、山梨糖醇、麦芽糖醇、甘露醇或异麦芽酮糖醇(paratinitt)混合。将混合物在研钵中研磨且在铝加热块中加热。记录熔化温度且在下表8中示出。
表8.芸香苷熔点
应注意,如同实施例9中描述的赤藓糖醇,木糖醇、麦芽糖醇以及山梨糖醇亦将芸香苷熔点(190℃)降低大约60度。相较于类似糖醇(即,甘露醇及异麦芽酮糖醇),此熔点降低是显著的。
实施例11:抗坏血酸防止芸香苷的褐变
将不同量的抗坏血酸钠与芸香苷(1.0g)、L-精氨酸(1.0g)以及赤藓糖醇(1.0g)混合。将各混合物在研钵中研磨且在122℃下在铝加热块中加热15min。将加热的混合物各自添加至经蒸馏H2O的等分试样中,以获得1%的芸香苷浓度(w/v)。经由0.45μm膜过滤器过滤样品。将各滤液(300μL)进一步用蒸馏水(2.7mL)稀释且接着立即测量550nm处的吸光度,且在24h后检测芸香苷溶液的褐变。各样品在时间0与24h之间的吸光度差异(ΔA550nm)在下表9中示出。
表9.防止芸香苷褐变反应
混合物编号 | 芸香苷:赤藓糖醇:精氨酸:抗坏血酸钠(mol:mol) | ΔA<sub>550nm</sub> |
9-01 | 1:3.8:1:0 | 0.0154 |
9-02 | 1:3.8:1:0.1 | 0.0018 |
9-03 | 1:3.8:1:0.2 | 0.0026 |
9-04 | 1:3.8:1:0.5 | 0.0035 |
9-05 | 1:3.8:1:1 | 0.0033 |
9-06 | 1:3.8:1:1.5 | 0.0038 |
9-07 | 1:3.8:1:2 | 0.0031 |
9-08 | 1:3.8:1:3 | 0.0020 |
结果显示,抗坏血酸钠将芸香苷组合物的褐变反应明显地降低高达8.5倍。
实施例12:抗坏血酸防止异槲皮苷的褐变
将不同量的抗坏血酸钠与异槲皮苷(1.0g)、L-精氨酸(1.0g)以及赤藓糖醇(1.5g)混合。将各混合物在研钵中研磨且在126℃下在铝加热块中加热15min。将加热的混合物各自添加至经蒸馏H2O的等分试样中,以获得1%的异槲皮苷浓度(w/v)。经由0.45μm膜过滤器过滤样品。将各滤液(300μL)进一步用蒸馏水(2.7mL)稀释且接着立即测量550nm处的吸光度且在24h后检测芸香苷溶液的褐变。各样品在时间0与24h之间的吸光度差异(ΔA550nm)在下表10中示出。
表10.防止异槲皮苷褐变反应
混合物编号 | 异槲皮苷:赤藓糖醇:精氨酸:抗坏血酸钠(mol:mol) | ΔA<sub>550nm</sub> |
10-01 | 1:4:1:0 | 0.0219 |
10-02 | 1:4:1:0.1 | 0.0060 |
10-03 | 1:4:1:0.2 | 0.0023 |
10-04 | 1:4:1:0.5 | 0.0042 |
10-05 | 1:4:1:1 | 0.0079 |
10-06 | 1:4:1:1.5 | 0.0041 |
10-07 | 1:4:1:2 | 0.0058 |
10-08 | 1:4:1:3 | 0.0087 |
抗坏血酸钠将异槲皮苷组合物的褐变反应降低高达9.5倍。
其他实施方案
本说明书中公开的所有特征可以任何组合形式组合。本说明书中公开的各特征可经服务相同、等效或类似目的的替代性特征替代。因此,除非另外明确说明,否则所公开的各特征仅为一系列通用等效或类似特征的实例。
根据以上描述,本领域技术人员可易于确定本发明的基本特征,且在不脱离本发明的精神及范畴的情况下可对本发明作出各种改变及修改以使其适应各种用途及条件。因此,其他实施方案亦处于以下权利要求的范围内。
Claims (21)
1.水溶性组合物,其包含O-糖基类黄酮化合物、L-精氨酸、糖醇以及抗坏血酸或其碱金属盐,其中所述O-糖基类黄酮化合物选自由以下组成的组:芸香苷、异槲皮苷以及橙皮苷,且所述糖基化合物与所述糖醇之间的摩尔比为1:4.0-12.0。
2.权利要求2所述的水溶性组合物,其中所述O-糖基类黄酮化合物与所述糖醇之间的摩尔比为1:4.0-8.0。
3.权利要求1所述的水溶性组合物,其中所述糖醇选自由以下组成的组:麦芽糖醇、赤藓糖醇、木糖醇以及山梨糖醇。
4.权利要求2所述的水溶性组合物,其中所述糖醇选自由以下组成的组:麦芽糖醇、赤藓糖醇、木糖醇以及山梨糖醇。
5.权利要求3所述的水溶性组合物,其中所述O-糖基类黄酮化合物与所述L-精氨酸之间的摩尔比为1:0.5-2.0。
6.权利要求5所述的水溶性组合物,其中所述O-糖基类黄酮化合物与所述L-精氨酸之间的摩尔比为1:0.7-1.5。
7.权利要求4所述的水溶性组合物,其中所述糖基化合物与所述L-精氨酸之间的摩尔比为1:0.5-2.0。
8.权利要求7所述的水溶性组合物,其中所述O-糖基类黄酮化合物与所述L-精氨酸之间的摩尔比为1:0.7-1.5。
9.权利要求3所述的水溶性组合物,其中所述O-糖基类黄酮化合物与所述抗坏血酸或其碱金属盐之间的摩尔比为1:0.02-0.5。
10.权利要求9所述的水溶性组合物,其中所述O-糖基类黄酮化合物与所述抗坏血酸或其碱金属盐之间的摩尔比为1:0.1-0.5。
11.权利要求4所述的水溶性组合物,其中所述O-糖基类黄酮化合物与所述抗坏血酸或其碱金属盐之间的摩尔比为1:0.02-0.5。
12.权利要求11所述的水溶性组合物,其中所述O-糖基类黄酮化合物与所述抗坏血酸或其碱金属盐之间的摩尔比为1:0.1-0.5。
13.权利要求3所述的水溶性组合物,其进一步包含维生素B1、维生素B3、维生素B6、维生素B9或维生素B12。
14.权利要求4所述的水溶性组合物,其进一步包含维生素B1、维生素B3、维生素B6、维生素B9或维生素B12。
15.权利要求3所述的水溶性组合物,其中所述组合物为医药药物、膳食补充剂、天然健康产品、化妆品、食品或饮料。
16.权利要求15所述的水溶性组合物,其中所述组合物为选自由以下组成的组的口服制剂:液体、胶囊剂、片剂、丸剂以及凝胶剂。
17.权利要求16所述的水溶性组合物,其中所述组合物呈胶囊剂或片剂形式,其各自由肠溶包衣形成。
18.权利要求15所述的水溶性组合物,其中所述组合物呈选自由以下组成的组的局部制剂形式:溶液剂、搽剂、洗剂、乳膏、软膏、糊剂、凝胶剂以及乳胶剂。
19.权利要求18所述的水溶性组合物,其中所述组合物为化妆品、皮肤护理品或医药药物。
20.用于产生水溶性O-糖基类黄酮组合物的方法,所述方法包含组合O-糖基类黄酮化合物、L-精氨酸、糖醇以及抗坏血酸或其碱金属盐以形成混合物,且在110℃至140℃下将所述混合物加热足以熔化所述混合物的时间,其中所述O-糖基类黄酮化合物、所述L-精氨酸、所述糖醇以及所述抗坏血酸或其碱金属盐各自呈固体形式;所述O-糖基类黄酮化合物选自由以下组成的组:芸香苷、异槲皮苷以及橙皮苷;且所述O-糖基类黄酮化合物与所述糖醇之间的摩尔比为1:4.0-12.0。
21.权利要求20所述的方法,其中所述糖醇选自由以下组成的组:麦芽糖醇、赤藓糖醇、木糖醇以及山梨糖醇。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/660,111 | 2019-10-22 | ||
US16/660,111 US11110109B2 (en) | 2019-10-22 | 2019-10-22 | Water soluble O-glycosyl flavonoid compositions and methods for preparing same |
PCT/JP2020/028322 WO2021079579A1 (en) | 2019-10-22 | 2020-07-21 | Water soluble o-glycosyl flavonoid compositions and methods for preparing same |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114423437A true CN114423437A (zh) | 2022-04-29 |
Family
ID=75490904
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202080066335.7A Pending CN114423437A (zh) | 2019-10-22 | 2020-07-21 | 水溶性o-糖基类黄酮组合物及其制备方法 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11110109B2 (zh) |
EP (1) | EP4048312A4 (zh) |
JP (1) | JP2022553165A (zh) |
CN (1) | CN114423437A (zh) |
WO (1) | WO2021079579A1 (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116076720A (zh) * | 2022-12-21 | 2023-05-09 | 河南中大恒源生物科技股份有限公司 | 一种水溶性芦丁粉的制备方法及应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6176552A (ja) * | 1984-09-21 | 1986-04-19 | Eisai Co Ltd | ルチン含有着色料 |
WO2010029913A1 (ja) * | 2008-09-11 | 2010-03-18 | 株式会社林原生物化学研究所 | 気力改善剤 |
RU2545905C1 (ru) * | 2013-12-16 | 2015-04-10 | Гарри Захарович Казиев | Водорастворимая фармацевтическая композиция l-аргинин-дигидрокверцетин и способ ее получения |
JP2015181399A (ja) * | 2014-03-24 | 2015-10-22 | アサヒ飲料株式会社 | ヘスペリジン含有飲料、苦味改善剤及び苦味改善方法 |
JP2015208241A (ja) * | 2014-04-24 | 2015-11-24 | 三栄源エフ・エフ・アイ株式会社 | 健康食品 |
Family Cites Families (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2451772A (en) | 1946-12-27 | 1948-10-19 | Univ Temple | Solubilization of rutin with methyl glucamine |
US2646428A (en) | 1949-09-20 | 1953-07-21 | Dausse Lab | Rutin derivatives and production thereof |
US2975168A (en) | 1957-07-04 | 1961-03-14 | Zyma Sa | Process of preparation of a tri-(hydroxyethyl) ether of rutin |
US4285964A (en) | 1979-08-30 | 1981-08-25 | Continental Pharma | Salts of (+)-catechine, their preparation and use, and compositions containing these salts |
EP0075626A1 (en) | 1981-09-29 | 1983-04-06 | American Cyanamid Company | Novel rutin nona- and deca(H-)sulfate salts, methods of preparing novel salts, and use of novel salts of complement inhibitors |
JPS59232054A (ja) | 1983-06-14 | 1984-12-26 | Nippon Shokuhin Kako Kk | 健康飲食品の製造方法 |
GB8628228D0 (en) | 1986-11-26 | 1986-12-31 | Inst Biolog Morya Dalnevostoch | Composition inhibiting pathological addiction to alcohol |
JP2926411B2 (ja) | 1989-03-08 | 1999-07-28 | 株式会社林原生物化学研究所 | α―グリコシル ルチンの製造方法とその用途 |
JP3212706B2 (ja) | 1992-08-05 | 2001-09-25 | 日本食品化工株式会社 | 飲食物 |
US7041652B1 (en) | 1998-08-27 | 2006-05-09 | Merck Patent Gmbh | Ascorbate-isoquercetin compositions |
WO2000054754A2 (en) | 1999-03-16 | 2000-09-21 | Merck Patent Gmbh | Composition comprising isoquercetin and ascorbic acid in a sustained release form |
JP2003171274A (ja) | 2001-12-07 | 2003-06-17 | Tomihiko Higuchi | 薬剤耐性菌感染症治療のための医薬組成物および消毒剤 |
US20060099239A1 (en) | 2002-04-15 | 2006-05-11 | Coleman Henry D | Dietary supplement for promoting removal of heavy metals from the body |
US7691425B2 (en) | 2003-09-29 | 2010-04-06 | San-Ei Gen F.F.I., Inc. | Method for manufacturing α-glycosylisoquercitrin, intermediate product and by-product thereof |
JP2005198642A (ja) | 2003-12-15 | 2005-07-28 | Yutaka Miyauchi | 柑橘類の果皮を原材料とする液状飲用物 |
CN101103121A (zh) | 2004-12-28 | 2008-01-09 | 三得利株式会社 | 槲皮素糖苷组合物及其制备方法 |
EP1902710A4 (en) | 2005-07-04 | 2009-12-02 | Univ Tokyo Medical & Dental | PHARMACEUTICAL COMPOSITION AND BEVERAGE COMPOSITION COMPRISING L-ARGININE |
WO2007114304A1 (ja) | 2006-03-29 | 2007-10-11 | San-Ei Gen F.F.I., Inc. | ベンゼン生成抑制剤およびベンゼン生成抑制方法 |
JP4914758B2 (ja) | 2006-05-09 | 2012-04-11 | 花王株式会社 | 液体調味料 |
JP4790561B2 (ja) | 2006-10-12 | 2011-10-12 | 東洋精糖株式会社 | フラボノイド組成物、その製造方法および用途 |
US20100204204A1 (en) | 2007-06-06 | 2010-08-12 | University Of South Florida | Nutraceutical co-crystal compositions |
WO2009018326A2 (en) | 2007-07-31 | 2009-02-05 | Limerick Biopharma, Inc. | Soluble pyrone analogs methods and compositions |
DE202008006741U1 (de) | 2008-05-19 | 2009-10-01 | Langhoff, Gertrud | Nährstoffzusammensetzung zur Vitalisierung |
CZ300846B6 (cs) | 2008-06-26 | 2009-08-26 | Agra Group, A. S. | Vodorozpustný prípravek na bázi flavanonol lignanu a zpusob jeho prípravy |
WO2009158031A2 (en) | 2008-06-27 | 2009-12-30 | Limerick Biopharma, Inc. | Methods and compositions for therapeutic treatment |
CN101301477B (zh) | 2008-07-04 | 2010-06-09 | 山西大学 | 异槲皮苷包合物及其制备方法 |
JP2010126503A (ja) | 2008-11-28 | 2010-06-10 | Yamano:Kk | L−アスコルビン酸の安定化方法、調製液体抽出物、固体状抽出物、半流動体抽出物 |
DE102008060803A1 (de) | 2008-12-01 | 2010-06-02 | C. & E. Fein Gmbh | Spule für eine Wickeleinrichtung |
US20120083460A1 (en) | 2009-03-25 | 2012-04-05 | San Ei Gen F.F.I., Inc. | Readily water-soluble isoquercitrin composition |
JP2010248148A (ja) | 2009-04-17 | 2010-11-04 | Rohto Pharmaceut Co Ltd | アドバンスド・グリケーション・エンド・プロダクツ分解剤 |
WO2011104667A1 (en) | 2010-02-25 | 2011-09-01 | Anthem Biosciences Private Limited | Basic aminoacid salts of polyphenols |
NL2004835C2 (en) | 2010-06-07 | 2011-12-08 | Univ Leiden | Process for extracting materials from biological material. |
ITUB20159549A1 (it) * | 2015-12-17 | 2017-06-17 | Labomar S R L | Composizione per la somministrazione di sostanze a bassa solubilita. |
JP6880757B2 (ja) | 2016-01-22 | 2021-06-02 | 大正製薬株式会社 | 経口液体組成物 |
KR102194884B1 (ko) | 2017-07-28 | 2020-12-24 | 타이요 카가꾸 가부시키가이샤 | 플라보노이드 포접 화합물의 제조 방법 |
US10603302B2 (en) | 2017-08-23 | 2020-03-31 | Roman Aleksandrovich | Water soluble flavonoids |
TWI761672B (zh) | 2018-04-23 | 2022-04-21 | 日商阿爾卑斯藥品工業股份有限公司 | O-醣苷基類黃酮之組成物 |
WO2019230013A1 (ja) | 2018-06-01 | 2019-12-05 | 太陽化学株式会社 | フラボノイド-シクロデキストリン包接化合物を含有する組成物 |
-
2019
- 2019-10-22 US US16/660,111 patent/US11110109B2/en active Active
-
2020
- 2020-07-21 WO PCT/JP2020/028322 patent/WO2021079579A1/en unknown
- 2020-07-21 CN CN202080066335.7A patent/CN114423437A/zh active Pending
- 2020-07-21 JP JP2022521674A patent/JP2022553165A/ja active Pending
- 2020-07-21 EP EP20878355.5A patent/EP4048312A4/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6176552A (ja) * | 1984-09-21 | 1986-04-19 | Eisai Co Ltd | ルチン含有着色料 |
WO2010029913A1 (ja) * | 2008-09-11 | 2010-03-18 | 株式会社林原生物化学研究所 | 気力改善剤 |
RU2545905C1 (ru) * | 2013-12-16 | 2015-04-10 | Гарри Захарович Казиев | Водорастворимая фармацевтическая композиция l-аргинин-дигидрокверцетин и способ ее получения |
JP2015181399A (ja) * | 2014-03-24 | 2015-10-22 | アサヒ飲料株式会社 | ヘスペリジン含有飲料、苦味改善剤及び苦味改善方法 |
JP2015208241A (ja) * | 2014-04-24 | 2015-11-24 | 三栄源エフ・エフ・アイ株式会社 | 健康食品 |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116076720A (zh) * | 2022-12-21 | 2023-05-09 | 河南中大恒源生物科技股份有限公司 | 一种水溶性芦丁粉的制备方法及应用 |
Also Published As
Publication number | Publication date |
---|---|
US11110109B2 (en) | 2021-09-07 |
EP4048312A1 (en) | 2022-08-31 |
TW202130352A (zh) | 2021-08-16 |
EP4048312A4 (en) | 2023-11-29 |
US20210113599A1 (en) | 2021-04-22 |
WO2021079579A1 (en) | 2021-04-29 |
JP2022553165A (ja) | 2022-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101535310B1 (ko) | 비타민 및 미네랄 보충제의 개선된 안정성 | |
US8895051B2 (en) | Flavoring systems for pharmaceutical compositions and methods of making such compositions | |
JPH11514629A (ja) | 安定な甲状腺ホルモン含有薬剤 | |
US11266671B2 (en) | Compositions of O-glycosyl flavonoids | |
SG192845A1 (en) | Diethylstilbestrol dosage form and use for the treatment of prostate or breast cancer | |
EP1858494B1 (en) | New soft gelatin capsules | |
KR20110116194A (ko) | 헤스페리딘 함유 조성물 | |
CN114423437A (zh) | 水溶性o-糖基类黄酮组合物及其制备方法 | |
JP5295571B2 (ja) | 疲労回復用内服用液剤 | |
JP5766021B2 (ja) | 安定な水性液剤 | |
CZ338897A3 (cs) | Farmaceutický přípravek obsahující tiagabin hydrochlorid a způsob jeho přípravy | |
US20090004290A1 (en) | Red yeast rice compound for cancer chemoprevention | |
JP4694132B2 (ja) | 内服用液剤、及びグルクロノラクトン含有溶液の味質変化防止液剤 | |
WO2007022105A2 (en) | Stable pharmaceutical compositions, processes for making the same, and methods of their use | |
TWI837375B (zh) | 水溶性o-醣苷基類黃酮組成物及其製備方法 | |
CA2417258A1 (en) | Flavoring systems for pharmaceutical compositions and methods of making such compositions | |
JP5823131B2 (ja) | 防風通聖散含有組成物 | |
JP5298526B2 (ja) | 内服用組成物 | |
JP5303086B2 (ja) | 経口液剤 | |
JP2007063223A (ja) | しみ又はそばかす予防又は治療用経口組成物及び食品 | |
JP2008088116A (ja) | 水性内服液剤組成物 | |
KR20220131186A (ko) | L-세린 또는 이의 약제학적으로 허용가능한 염의 액상 제제 및 이의 제조방법 | |
RU2020138109A (ru) | Композиции о-гликозилфлавоноидов | |
RU2173996C2 (ru) | Фармацевтическая композиция, содержащая гидрохлорид тиагабина, и способ ее получения | |
JP4932253B2 (ja) | 経口用液体組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |